Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

BCL2 Biological Pathways Reviews

Videos

Asher Chanan-Khan, MD
Videos
11/14/2022
Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Asher Chanan-Khan, MD, argues in...
11/14/2022
Oncology
Jonathan Kaufman, MD, Talks Targeting BCL-2 With Venetoclax and Dexamethasone in R/R MM
Videos
05/11/2021
Jonathan Kaufman, MD, discusses his study about targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory MM.
Jonathan Kaufman, MD, discusses his study about targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory MM.
Jonathan Kaufman, MD, discusses...
05/11/2021
Oncology
Nirav Shah, MD
Videos
08/05/2024
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma...
08/05/2024
Oncology
Curtis Lachowiez, MD
Videos
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology
Videos
08/02/2024
Ticiana Leal, MD, discusses the course of treatment she would take for a patient with early-stage NSCLC.
Ticiana Leal, MD, discusses the course of treatment she would take for a patient with early-stage NSCLC.
Ticiana Leal, MD, discusses the...
08/02/2024
Oncology
Rene Adam, MD, PhD
Conference Coverage
08/02/2024
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses...
08/02/2024
Oncology
Ajai Chari, MD
Videos
07/31/2024
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.
Ajai Chari, MD, participated in...
07/31/2024
Oncology
Ajai Chari, MD
Videos
07/31/2024
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.
Ajai Chari, MD, participated in...
07/31/2024
Oncology
Elizabeth Brem, MD
Videos
07/29/2024
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares...
07/29/2024
Oncology
Elizabeth Brem, MD
Videos
07/29/2024
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates &...
07/29/2024
Oncology
Rahul Banerjee, MD
Videos
07/28/2024
At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.
At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology
Amrita Krishnan, MD
Videos
07/28/2024
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates &...
07/28/2024
Oncology
OLN

BCL2

ALIASES

BCL2 Apoptosis Regulator; PPP1R50; Bcl-2; Protein Phosphatase 1, Regulatory Subunit 50; Apoptosis Regulator Bcl-2; B-Cell CLL/Lymphoma 2; BCL2, Apoptosis Regulator 2

Tumor cells have many characteristics, including genomic instability and oncogene activation, which should lead to apoptosis.1 In a bid to survive, tumor cells may become dependent on the BCL-2 protein.2 Certain cancer cells will overexpress BCL-2, which in turn impedes apoptosis and facilitates tumor growth and resistance to chemotherapy.3 These malignant cells that depend on BCL-2 for survival are likely to be sensitive to BCL-2 modulation.4

Understanding the Role of BCL2

This animation discusses the role of BCL2 in normal cell function and explains the effects of disruptions in the BCL2 gene on cell signaling.

Expression in Cancer

High expression of BCL-2 occurs in a variety of cancer types. The graphic below displays cases in each cancer type (up to a certain percentage) that have been reported to overexpress BCL-2.

Breast Cancer
75%
Chronic Lymphocytic Leukemia
95%
Acute Myeloid Leukemia
87%
Follicular Lymphoma
90%
Diffuse Large B-Cell Lymphoma
20%
Prostate Cancer
55%
Head and Neck Cancer
12.8%
Small Cell Lung Cancer
90%
Non-Small Cell Lung Cancer
58%
Acute Lymphoblastic Leukemia
99%

Resources

News
09/25/2020
Study findings support the evaluation of novel strategies for the treatment of patients with HIV-associated DLBCL expressing BCL-2.
Study findings support the evaluation of novel strategies for the treatment of patients with HIV-associated DLBCL expressing BCL-2.
Study findings support the...
09/25/2020
Oncology
News
06/05/2020
Study findings show that resistance to venetoclax therapy in patients with MCL is primarily associated with non-BCL2 gene mutations.
Study findings show that resistance to venetoclax therapy in patients with MCL is primarily associated with non-BCL2 gene mutations.
Study findings show that...
06/05/2020
Oncology
News
03/29/2018
Dual targeting of BTK and BCL2 may improve outcomes in patients with mantle cell lymphoma and a poor prognosis.
Dual targeting of BTK and BCL2 may improve outcomes in patients with mantle cell lymphoma and a poor prognosis.
Dual targeting of BTK and BCL2...
03/29/2018
Oncology
News
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Podcasts

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology
Michael Hall, MD, Fox Chase Cancer Center
Podcasts
12/20/2022
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his...
12/20/2022
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
11/15/2022
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares...
11/15/2022
Oncology
OLN favicon
Podcasts
07/29/2022
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses...
07/29/2022
Oncology
Ruth He, MD, Lombardi Comprehensive Cancer Center
Podcasts
07/22/2022
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings...
07/22/2022
Oncology
Arndt Vogel, MD, Hannover Medical School
Podcasts
07/14/2022
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results...
07/14/2022
Oncology
Petros Grivas, MD, Fred Hutchinson Cancer Center
Podcasts
06/22/2022
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares...
06/22/2022
Oncology
Robert Jones, MD
Podcasts
06/21/2022
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results...
06/21/2022
Oncology
David O'Malley
Podcasts
06/20/2022
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast...
06/20/2022
Oncology

Interactive

Test Your Knowledge
09/22/2021
True or false: Although patients with CLL achieve durable responses through novel inhibitor treatments, such as BTK inhibitors, BCL-2 inhibitors are nonapplicable.
True or false: Although patients with CLL achieve durable responses through novel inhibitor treatments, such as BTK inhibitors, BCL-2 inhibitors are nonapplicable.
True or false: Although patients...
09/22/2021
Oncology
Test Your Knowledge
10/13/2020
True or False: Certain cancer cells overexpress BCL-2, which promotes apoptosis and reduces tumor growth and resistance to chemotherapy.
True or False: Certain cancer cells overexpress BCL-2, which promotes apoptosis and reduces tumor growth and resistance to chemotherapy.
True or False: Certain cancer...
10/13/2020
Oncology
Test Your Knowledge
09/01/2020
True or False: Resistance to venetoclax therapy in patients with mantle cell lymphoma is primarily associated with non-BCL2 gene mutations.
True or False: Resistance to venetoclax therapy in patients with mantle cell lymphoma is primarily associated with non-BCL2 gene mutations.
True or False: Resistance to...
09/01/2020
Oncology
Test Your Knowledge
08/24/2020
True or False: Dual targeting of BTK and BCL2 can improve outcomes in patients with MCL and a poor prognosis.
True or False: Dual targeting of BTK and BCL2 can improve outcomes in patients with MCL and a poor prognosis.
True or False: Dual targeting of...
08/24/2020
Oncology
Quiz
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology
Quiz
08/08/2024
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase...
08/08/2024
Oncology
Quiz
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology
Quiz
07/15/2024
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis...
07/15/2024
Oncology
Quiz
06/28/2024
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in...
06/28/2024
Oncology
Quiz
06/26/2024
What adjuvant treatment would you recommend?
What adjuvant treatment would you recommend?
What adjuvant treatment would...
06/26/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement